Abstract

A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call